Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: A multicentric analysis of feasibility and rates of pathologic complete response

Chemotherapy

Volumn 59, Issue 5, 2014, Pages 387-394

  Kern, Peter ^a,e   Kalisch, Anne ^a   Kolberg, Hans Christian ^b   Kimmig, Rainer ^a   Otterbach, Friederich ^a   Von Minckwitz, Gunter ^d,e   Sikov, William M ^g   Pott, Dirk ^c   Kurbacher, Christian ^f  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Women's Department Marienhospital Bottrop   (Germany)

^c Clinic for Hematology and Oncology   (Germany)

^d German Breast Group   (Germany)

^e Breast Center Düsseldorf Luisenkrankenhaus   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g BROWN UNIVERSITY   (United States)

Author keywords

Carboplatin; Neoadjuvant chemotherapy; Pathologic complete response; Triple negative breast cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; ANTHRACYCLINE; CREATININE; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG INTOXICATION; DYSESTHESIA; EARLY CANCER; EDEMA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LEUKOPENIA; LONG TERM SURVIVAL; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; VOMITING; ADJUVANT CHEMOTHERAPY; ARTHRALGIA; CANCER SURGERY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; IMMUNOPHENOTYPING; INCIDENCE; INFECTION; LIVER DISEASE; LYMPH NODE DISSECTION; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; PARTIAL MASTECTOMY; PERIPHERAL NEUROPATHY; PREVALENCE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; CLINICAL TRIAL; FEMALE; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEASIBILITY STUDIES; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84900886506     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000362756     Document Type: Article

References (58)

1. Foulkes WD, Smith IE, Reis-Filho JS: Triplenegative breast cancer. N Engl J Med 2010; 363: 1938-1948.
2. Irvin WJ Jr, Carey LA: What is triple-negative breast cancer? Eur J Cancer 2008; 44: 2799-2805.
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007; 109: 1721-1728.
4. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
5. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N: Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-1927.
6. Carey L, Winer E, Viale G, Cameron D, Gianni L: Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7: 683-692.
7. Heitz F, Harter P, Lueck HJ, et al: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009; 45: 2792-2798.
8. Lin NU, Vanderplas A, Hughes ME, et al: Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN) (abstract 543). J Clin Oncol 2009; 27: 15s.
9. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
10. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
11. Kern P, Badiian M, von Minckwitz G, et al: Triple negative breast cancer: prognosis of triple-negative breast cancers and non-triplenegative breast cancers in a large registry of certified breast units (abstract). Cancer Res 2012; 72: 22.
12. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
13. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
14. Foulkes WD, Stefansson IM, Chappuis PO, et al: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-1485.
15. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
16. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
17. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819.
18. Lips EH, Mulder L, Oonk A, et al: Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013; 108: 2172-2177.
19. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant cisplatin in triplenegative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
20. von Minckwitz G, Martin M: Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol 2012; 23(suppl 6):vi35-vi39.
21. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
22. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC->T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC->TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients (abstract 52). Annu San Antonio Breast Cancer Symp, San Antonio, December 2006.
23. Chang HR, Glaspy J, Allison MA, et al: Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010; 116: 4227-4237.
24. Chen XS, Nie XQ, Chen CM, et al: Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010; 21: 961-967.
25. Roy V, Pockaj BA, Northfelt DW, et al: N0338 phase ll trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage ll or lll breast cancer (abstract). Journal Clin Oncol 2008; 26: 563.
26. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
27. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 2010; 6: 195-197.
28. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
29. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.03. 2010. http://evs.nci.nih.gov/ftp1/CTCAE/ C T C A E-4 . 0 3-2 0 1 0-0 6-1 4-QuickReference-8.5x11.pdf (accessed July 3, 2013).
30. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
31. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
32. Vasey PA, Atkinson R, Coleman R, et al: Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001; 84: 170-178.
33. Zarogoulidis K, Kontakiotis T, Hatziapostolou P, et al: A phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer 2001; 32: 281-287.
34. Loibl S, Jackisch C, Gade S, et al: Neoadjuvant chemotherapy in the very young, 35 years of age or younger (abstract). Cancer Res 2012; 72:S23-S21.
35. Alba E, Chacon JI, Lluch A, et al: A randomized phase II trial of platinum salts in basallike breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 2012; 136: 487-493.
36. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
37. Sikov WM, Dizon DS, Strenger R, et al: Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009; 27: 4693-4700.
38. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
39. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23: 5983-5992.
40. von Minckwitz G, Untch M, Blohmer JU, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
41. Cortazar P, Zhang L, Untch M, et al: Metaanalysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (abstract). Cancer Res 2012; 72:S21-S11.
42. Hurley J, Reis IM, Rodgers SE, et al: The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 2013; 138: 783-794.
43. Shamseddine AI, Farhat FS: Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011; 57: 468-487.
44. von Minckwitz G, Untch M, Nuesch E, et al: Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-156.
45. Huober J, von Minckwitz G, Denkert C, et al: Effect of neoadjuvant anthracycline-taxanebased chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-140.
46. Cheang M, Chia SK, Tu D, et al: Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF (abstract 519). J Clin Oncol 2009; 27: 15s.
47. Di Leo A, Desmedt C, Bartlett JM, et al: HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011; 12: 1134-1142.
48. Tanner M, Isola J, Wiklund T, et al: Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-2436.
49. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al: Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012; 30: 11-18.
50. Liao Y, Fan Y, Wan Y, Li J, Peng L: Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study. Chemotherapy 2013; 59: 207-213.
51. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
52. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25: 3808-3815.
53. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
54. Ewer MS, Von Hoff DD, Benjamin RS: A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin 2011; 7: 363-372.
55. Karp J, Blackford A, Visvanathan K, et al: Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience (abstract). Cancer Res 2012; 72:S23-S25.
56. Jinno H, Matsuda S, Hayashida T, et al: Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes. Chemotherapy 2012; 58: 364-370.
57. von Minckwitz G, Schneeweiss A, Salat CT, et al: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto-GBG 66) (abstract). J Clin Oncol 2013; 31: 1004.
58. Sikov W, Berry D, Perou C, et al: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (abstract S5-01). 36th Annu San Antonio Breast Cancer Symp, San Antonio, December 10-14, 2013.